Holen Sie sich die Stockscreener-App
1.58
1.25%
-0.02
Schlusskurs vom Vortag:
$1.60
Offen:
$1.62
24-Stunden-Volumen:
153.63K
Relative Volume:
0.29
Marktkapitalisierung:
$227.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+14.49%
1M Leistung:
-20.60%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.56
$1.65
1-Wochen-Bereich:
$1.3707
$1.97
52-Wochen-Spanne:
$1.27
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Firmenname
Veraxa Biotech Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare VRXA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
1.6099 | 226.25M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
521.32 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.44 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.73 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.36 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.19 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag Aktie (VRXA) Neueste Nachrichten
Veraxa Biotech (VRXA) Insider Trading Activity 2026 - MarketBeat
Veraxa Biotech AG (NASDAQ: VRXA) Names Raju Willener as CFO Following De-SPAC Completion - Kalkine Media
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer - TradingView
VRXA Rises As Veraxa Biotech AG Draws Trader Focus - timothysykes.com
Veraxa Biotech AG Company Profile & Introduction - Moomoo
VRXA Jumps As Traders Focus On Biotech Breakout Setup - timothysykes.com
VRXA Should I Buy - Intellectia AI
VERAXA Biotech Appoints Veteran Finance Executive Raju Willener as CFO to Drive Capital Strategy and Oncology Pipeline Growth - citybuzz -
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Veraxa Biotech AG Announces Chief Financial Officer Changes - marketscreener.com
Veraxa Biotech stock rises after naming Raju Willener as CFO - Investing.com India
Veraxa Biotech stock rises after naming Raju Willener as CFO By Investing.com - Investing.com South Africa
Veraxa Biotech names Raju Willener as chief financial officer By Investing.com - Investing.com South Africa
Finance veteran behind CHF 30B portfolios joins Veraxa Biotech (VRXA) as CFO - Stock Titan
Veraxa Biotech names Raju Willener as chief financial officer - Investing.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer - 富途牛牛
Veraxa Biotech (VRXA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Insider Buys Additional CHF75k In Veraxa Biotech Stock - simplywall.st
Veraxa Biotech (VRXA) Stock Price, News & Analysis - MarketBeat
Veraxa Biotech (VRXA) Stock Chart and Price History 2026 - MarketBeat
Veraxa Biotech (VRXA) director adds 50K shares in open-market buy - Stock Titan
Veraxa Biotech (VRXA) CEO now holds 5,000 ordinary shares - Stock Titan
VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation T - Benzinga
Early lab data advance Veraxa (Nasdaq: VRXA) autoimmune AOC - stocktitan.net
Veraxa and Secarna report positive early results from AOC study By Investing.com - Investing.com India
Veraxa Biotech AG - Via Ritzau
VERAXA Biotech Advances VXA-222 Cancer Program Beyond Discovery Phase, Strengthens IP Portfolio - citybuzz -
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan
Veraxa Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -
Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies - Yahoo Finance
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan
VERAXA Biotech (VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms - usatoday.com
Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada
Veraxa Biotech files first BiTAC patent applications in 2026 - Investing.com
Finanzdaten der Veraxa Biotech Ag-Aktie (VRXA)
Es liegen keine Finanzdaten für Veraxa Biotech Ag (VRXA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Veraxa Biotech Ag-Aktie (VRXA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Antz Christoph Rudiger | Chief Executive Officer |
Aug 27 '26 |
Buy |
1.53 |
5,000 |
7,650 |
5,000 |
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):